Observational Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 26, 2023; 11(27): 6424-6430
Published online Sep 26, 2023. doi: 10.12998/wjcc.v11.i27.6424
Helicobacter pylori eradication treatment for primary gastric diffuse large B-cell lymphoma: A single-center analysis
Makoto Saito, Akio Mori, Sayaka Kajikawa, Emi Yokoyama, Minoru Kanaya, Koh Izumiyama, Masanobu Morioka, Takeshi Kondo, Zen-Ichi Tanei, Ai Shimizu
Makoto Saito, Akio Mori, Sayaka Kajikawa, Emi Yokoyama, Minoru Kanaya, Koh Izumiyama, Masanobu Morioka, Takeshi Kondo, Blood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, Japan
Zen-Ichi Tanei, Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo 060-8638, Hokkaido, Japan
Ai Shimizu, Department of Surgical Pathology, Hokkaido University Hospital, Sapporo 060-8648, Hokkaido, Japan
Author contributions: Saito M designed this study; Tanei ZI and Shimizu A involved in pathological procedure; all authors made substantial contributions to acquisition of data, or analysis and interpretation of data; took part in drafting the article; and agree to be accountable for all aspects of the work.
Institutional review board statement: This study was conducted in accordance with the World Medical Association Declaration of Helsinki, and this study was reviewed and approved by the Aiiku Hospital Clinical Research Review Board (Sapporo).
Informed consent statement: All patients provided written informed consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Makoto Saito, MD, PhD, Chief Doctor, Blood Disorders Center, Aiiku Hospital, Chuo-ku Minami 4 Nishi 25, Sapporo 064-0804, Hokkaido, Japan. ikyoku@aiiku-hp.or.jp
Received: June 23, 2023
Peer-review started: June 23, 2023
First decision: August 9, 2023
Revised: August 11, 2023
Accepted: August 29, 2023
Article in press: August 29, 2023
Published online: September 26, 2023
Processing time: 78 Days and 15.7 Hours
Core Tip

Core Tip: Unlike the already established effect of Helicobacter pylori (H. pylori) eradication on gastric mucosa-associated lymphoid tissue lymphoma, its therapeutic effect on primary gastric diffuse large B-cell lymphoma (DLBCL) is not clear. Previously, we reported 1 successful case and 2 failed cases. We report here on 3 new cases, and we considered a total of 6 cases. Three patients with a single lesion achieved complete remission, in contrast, 3 patients with multiple lesions persisted or progressed. We believe it is worthwhile to attempt H. pylori eradication for an elderly patient with a single lesion and a small tumor burden of primary gastric DLBCL.